Melanoma Molecular Maps Projects

Padova

Clinical Trial Database

A systematic collection of the most significant results of clinical trials for the management of patients with malignant melanoma. Ranging from randomized controlled clinical studies and meta-analyses of traditional therapies to feasibility trials of the most innovative therapeutic approaches.

Title:
Aim of Trial
Therapeutic Prognostic Other
Type of Therapy
Medical Therapy Biotherapy
Chemotherapy
Immunotherapy
Molecularly targeted agents
Other


Drug list


Radiotherapy

Surgery

Type of Study
Phase:
Study design:
Tumor:
Setting:
Year:

To reset the form Click Here

17-AAG (HSP90 inhibitor) for metastatic melanoma  
Acral lentiginous melanoma: clinical profile and risk of other tumors  
Adoptive cell therapy plus intensive myeloablative chemoradiation for metastatic melanoma  
Adoptive therapy plus IL2 versus IL2 alone for stage III melanoma  
Anti-CTLA4 antibody plus peptide vaccination for adjuvant treatment of melanoma (ongoing)  
Arsenic trioxide (ATO) for the treatment of advanced melanoma  
AZD2171 for the treatment of advanced melanoma (ongoing)  
BCG plus DTIC versus BCG versus observation for the adjuvant treatment of melanoma (E1673)  
Bevacizumab + carboplatin + paclitaxel for metastatic melanoma  
Bevacizumab versus observation for the adjuvant treatment of melanoma (ongoing)  
Bevacizumab with versus without low dose IFN alpha (2b) for metastatic melanoma  
BI 2536 for the treatment of advanced tumors including melanoma (EORTC 90061) (ongoing)  
Biochemotherapy (cisplatin + DTIC + IL-2 + INF alpha) for metastatic melanoma  
Biochemotherapy for mucosal melanoma of head and neck  
Biochemotherapy or chemotherapy with versus without tamoxifen: a meta-analysis  
Biochemotherapy (sequential) with temozolomide and IL-2 for metastatic melanoma  
Biochemotherapy versus chemotherapy for metastatic melanoma: a meta-analysis (1)  
Biochemotherapy versus chemotherapy for metastatic melanoma: a meta-analysis (2)  
Biochemotherapy versus chemotherapy for the treatment of metastatic melanoma  
Biochemotherapy versus polychemotherapy: the ECOG 3695 trial (E3695)  
Biochemotherapy with IL-2 at different dosages for the treatment of metastatic melanoma  
Bortezomib plus temozolomide in advanced refractory melanoma (ongoing)  
Brachytherapy versus enucleation for ocular melanoma  
Carbon ion radiotherapy (CIR) for mucosal melanoma of head and neck  
Central nervous system metastasis from uveal melanoma  
Chemosensitivity based treatment versus DTIC in metastatic melanoma (ongoing)  
Chemotherapy for the adjuvant treatment of melanoma: a meta-analysis  
Chest X-rays for melanoma follow-up  
Cilengitide for the treatment of advanced melanoma  
Cisplatin +DTIC + BCNU with or without tamoxifen for the treatment of advanced melanoma  
Cisplatin plus DTIC with versus without IFN alpha (2b) plus IL-2 for advanced melanoma  
Clinical outcome and compliance with NCCN guidelines  
CNTO 95 antibody for metastatic melanoma (ongoing)  
CP-675,206 antibody for the treatment of advanced melanoma (ongoing)  
Dacarbazine-based versus comparator chemotherapy for metastatic melanoma: a meta-analysis  
Dacarbazine versus combination regimens for metastatic melanoma: a meta-analysis  
Dacarbazine with versus without ipilimumab in advanced melanoma (ongoing)  
Dacarbazine with versus without sorafenib as first line therapy for advanced melanoma  
Decitabine plus high dose IL2 in patients with advanced melanoma and renal cell carcinoma  
Denileukin difitox alone vs vaccine vs combination for metastatic melanoma (ongoing)  
Denileukin difitox for the treatment of metastatic melanoma (ongoing)  
Dermoscopy versus unaided eye for the diagnosis of melanoma: a meta-analysis (1)  
Dermoscopy versus unaided eye for the diagnosis of melanoma: a meta-analysis (2)  
Desmoplastic melanoma: a case-control comparison with other melanomas  
Desmoplastic melanoma: a clinicopathologic analysis  
Desmoplastic melanoma: an observational study  
Disseminated tumor cells in uveal melanoma  
Docetaxel, cisplatin and temozolomide for metastatic melanoma: first experience  
DTIC and IFN-alpha with or without IL-2 for the treatment of metastatic melanoma: a DeCOG trial  
DTIC + BCNU + cisplatin + tamoxifen versus DTIC alone for the treatment of advanced melanoma  

 1 2 3 4 5 6 7  [Next >>]

Search the site


Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |


Melanoma News


NCBI's Disclaimer and Copyright notice